Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

NCR graphs - Age specific incidence rates

- All cancer age-specific incidence rates, including non-melanoma skin cancer, males, Lebanon, 2005, 2010, 2015
- All cancer age-specific incidence rates, including non-melanoma skin cancer, females, Lebanon, 2005, 2010, 2015

- All cancer age-specific incidence rates, excluding non-melanoma skin cancer, males, Lebanon, 2005, 2010, 2015
- All cancer age-specific incidence rates, excluding non-melanoma skin cancer, females, Lebanon, 2005, 2010, 2015

- Oesophagus cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Oesophagus cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Estomac cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Estomac cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Colo-rectal cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Colo-rectal cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Liver cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Liver cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Gallbladder and extrahepatic bilary tract cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Gallbladder and extrahepatic bilary tract cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Pancreas cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Pancreas cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Larynx cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Larynx cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Trachea-bronchus-lung cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Trachea-bronchus-lung cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Bone cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Bone cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Melanoma age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Melanoma age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Non-melanoma skin cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Non-melanoma skin cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Breast cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Breast cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Col uteri cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015
- Corpus uteri cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015
- Ovary cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Prostate cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Testis cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015

- Kidney cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Kidney cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Bladder cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Bladder cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Brain and central nervous system cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Brain and central nervous system cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Thyroid cancer age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Thyroid cancer age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Hodgkin's lymphoma age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Hodgkin's lymphoma age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Non-Hodgkin lymphoma age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Non-Hodgkin lymphoma age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Multiple Myeloma age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Multiple Myeloma age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Lymphoid leukemia age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Lymphoid leukemia age-specific incidence rates, females, Lebanon, 2005, 2010, 2015

- Myeloid leukemia age-specific incidence rates, males, Lebanon, 2005, 2010, 2015
- Myeloid leukemia age-specific incidence rates, females, Lebanon, 2005, 2010, 2015
 
    ...
    172
    ...
ATC Name B/G Ingredients Dosage Form Price
J01XA01 ZERMACIN G Vancomycin (HCl) - 0.5g 0.5g Injectable sterile lyophilised powder for solution 5,875,791 L.L
J01XA01 VANCOLON G Vancomycin (HCl) - 0.5g 0.5g Injectable lyophilised powder for solution 1,009,226 L.L
J01XA01 ZERMACIN G Vancomycin (HCl) - 1g 1g Injectable lyophilised powder for solution 1,066,115 L.L
J01XA01 ZERMACIN G Vancomycin (HCl) - 1g 1g Injectable lyophilised powder for solution 6,911,190 L.L
J01XA01 VANCOMYCIN HIKMA G Vancomycin (HCl) - 500mg 500mg Injectable powder for solution 998,475 L.L
J01XA01 VOXIN G Vancomycin (HCl) - 500mg 500mg Injectable powder for solution 546,944 L.L
J01XA01 VANCO MEDIS G Vancomycin - 1g 1g Injectable lyophilisate for solution 1,276,650 L.L
J01XA01 VANCO MEDIS 500MG G Vancomycin - 500mg 500mg Injectable powder for solution 998,475 L.L
J01XA01 VANCOMYCINE VIATRIS 500MG G Vancomycin - 500mg 500mg Injectable dry powder for solution 805,988 L.L
G04BE09 VERDA G Vardenafil (HCl) - 10mg 10mg Tablet, orally disintegrating 1,023,880 L.L
G04BE09 LEVITRA B Vardenafil (HCl) - 20mg 20mg Tablet, film coated 2,660,808 L.L
G04BE09 LEVIDOR G Vardenafil (HCl) - 20mg 20mg Tablet 401,809 L.L
J07BK01 VARIVAX B Varicella virus, live attenuated - 1350PFU Injectable powder for suspension+diluent 4,102,751 L.L
J07BK01 VARILRIX + SOLVENT IN SYRINGE B Varicella virus, live attenuated - ?1033 PFU ?1033 PFU Injectable lyophilised powder for solution+diluent 3,473,833 L.L
J07BK01 VARICELLA VACCINE LIVE BioTech Varicella-herpes zoster virus (Oka strain), grown in human diploid cells (SV-cell line), live attenuated - Injectable suspension 3,104,276 L.L
D02AC VASIDEX G Vaseline pure - 15g 15g Ointment 78,071 L.L
D02AC VASELINE PURE G Vaseline pure - 20g 20g Ointment 103,668 L.L
L04AA33 ENTYVIO BioTech Vedolizumab - 108mg 108mg Injectable solution 84,211,194 L.L
L04AA33 ENTYVIO BioTech Vedolizumab - 108mg 108mg Injectable solution 84,211,194 L.L
L04AA33 ENTYVIO BioTech Vedolizumab - 300mg 300mg Injectable powder for concentrate for solution 152,492,033 L.L
L01EC01 ZELBORAF B Vemurafenib - 240mg 240mg Tablet, film coated 142,041,587 L.L
L01XX52 VENCLEXTA B Venetoclax - 100mg 100mg Tablet 707,858,935 L.L
L01XX52 VENCLEXTA B Venetoclax - 10mg 10mg Tablet 12,966,030 L.L
L01XX52 VENCLEXTA B Venetoclax - 10mg week 1, Venetoclax - 50mg week 2, Venetoclax - 100mg week 3&4 Tablet 190,943,809 L.L
L01XX52 VENCLEXTA B Venetoclax - 50mg 50mg Tablet 31,367,183 L.L
N06AX16 EFEXOR XR B Venlafaxine (HCl) - 150mg 150mg Capsule, sustained release 817,056 L.L
N06AX16 EFEXOR XR B Venlafaxine (HCl) - 75mg 75mg Capsule, sustained release 732,394 L.L
N06AX16 DEFAXINE G Venlafaxine (HCl) - 75mg 75mg Capsule, extended release 724,395 L.L
N06AX16 DEPREVIX HELLAS G Venlafaxine - 150mg 150mg Capsule, prolonged release 968,910 L.L
N06AX16 VENLAFAXINE ARROW GENERIQUES LP G Venlafaxine - 150mg 150mg Tablet, prolonged release 987,724 L.L
    ...
    172
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025